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GENETIC MANIPULATIONS OB CELLS AND TIS- 
SUES FOR THE TREATMENT OF RESTENOSIS 
Michael]-. Mann, MD 
Brigham and Women's Hospital~Harvard Medical School 
Boston, Mass 
Recurrent narrowing of arteries following percu- 
taneous angioplasty, atherectomy, or other disoblit- 
erative technique is a common clinical problem that 
severely limits the durability of these procedures for 
patients with atherosclerotic occlusive diseases. In 
the case of balloon angioplasty, restenosis occurs in 
approximatcly 30% to 40% of treated coronary 
lesions and 30% to 50% of superficial femoral artery 
lesions within the first year. Intravascular stents may 
reduce the restenosis rates. However, the incidence 
remains high, and long-term data are limited, 
Despite technological dvances in the development 
of minimally invasive and endovascular pproaches 
to treat arterial occlusions, the full benefit of these 
gains awaits he solution of this fundamental biolog- 
ic problem. 
Restenosis an attractive target for gene therapy 
not only because of its frequency but also because it
is a local tissue reaction that develops precisely at a 
site of intervention to which access has already been 
achieved. A potential advantage of the genetic 
approach over more conventional pharmacothera- 
pies is that a single dose ofa gene therapy agent may 
have a prolonged biological effect. The appropriate 
genetic modification, performed locally at the time 
of angioplasty, could induce a long-term benefit in 
patency by altering the healing response, The poten- 
tial role for gene therapy in the prevention of 
restenosis will depend on the identification of an 
appropriate molecular target, a suitable vector sys- 
tem for efficiently targeting vessel wall cells, and 
methods of achieving local delivery without produc- 
ing undue damage or distal tissue ischemia. 
Presently, considerable hurdles remain despite sig- 
nificant progress in each of these areas. 
Restenosis is composed of a contraction and 
fibrosis of the vessel wall known as remodeling, and 
an active growth of a fibrocellular lesion composed 
primarily of VSMCs and extracellular matrix. The 
latter process, known as neointimal hyperplasia, 
involves the stimulation of the normally "quiescent" 
VSMCs in: the arterial media into the "activated" 
state characterized by rapid proliferation and migra- 
tion. A number of growth factors are believed to 
play a role in the stimulation of VSMCs during 
neointimal hyperplasia, including platelet-derived 
growth factor (PDGF), basic fibroblast growth fac- 
tor (bFGF), transforming rowth factor beta (TGF- 
[3), and angiotensin II. Activated VSMCs have also 
been found to produce a variety of enzymes, 
cytokines, adhesion molecules, and other proteins 
that not only enhance the inflammatory response 
within the vessel wall but also stimulate further vas- 
cular cell abnormality.1 
Although it is now thought hat remodeling may 
account for the majority of late lumen loss after bal- 
loon dilation of atherosclerotic vessels, proliferation 
has been the predominant target of experimental 
genetic interventions. There have been two general 
approaches: "cytostatic," in which cells are prevent- 
ed from progressing through the cell cycle to mito- 
sis, and cytotoxic, in which cell death is induced. A 
group of molecules known as cell cycle regulatory 
proteins acts at different points along the cell cycle, 
mediating progression toward division. It has been 
hypothesized that by blocking expression of the 
genes for one or more of these proteins, one could 
prevent he progression of VSMCs through the cell 
cycle and inhibit neointimal hyperplasia. Morishita 
et al 2 demonstrated near complete inhibition of 
neointimal hyperplasia fter carotid balloon i jury, 
through HVJ-liposome-mediated transfection of 
the vessel wall with a combination of antisense ODN 
against cell cycle regulatory genes. Arrest of the cell 
cycle through antisense blockade of either of two 
proto-oncogenes, c-myb or c-myc, has been found to 
inhibit neointimal hyperplasia in models of arterial 
balloon injury, a, 4 although the specific antisense 
mechanism of the ODN used in these studies has 
subsequently been questioned. 5 
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In addition to  transfection ofcells with antisense 
ODN, cell cycle arrest can also be achieved through 
manipulation of transcription factor activity. The 
activity of a number of cell cycle regulatory genes is 
influenced by a single transcription factor lmown as 
E2F. In quiescent cells, E2F is bound to a complex 
of other proteins, including a protein known as the 
retinoblastoma gene product (Rb), that prevent its 
interaction with chromosomal DNA and its stimula- 
tion of gene activity. In proliferating cells, E2F is 
released, resulting in cell cycle gene activation. A
transcription factor decoy bearing the consensus- 
binding sequence recognized by E2F can be used as 
a means to inhibit cellular proliferation. Morishita et 
al6 demonstrated the us of this strategy to prevent 
VSMC proliferation and neointimal hyperplasia fter 
rat carotid balloon injury. Alternatively, Chang et al7 
showed that localized arterial infection with a repli- 
cation-defective adenovirus encoding a nonphos- 
phorylatable, constitutively active form of Rb at the 
time of balloon angioplasty significantly reduced 
smooth muscle cell proliferation and neointima for- 
mation in both the rat carotid and porcine femoral 
artery models of restenosis. Similar results were also 
obtained by adenovirus-mediated overexpression f 
a "natural" inhibitor of cell cycle progression, the 
cyclin dependent kinase inhibitor, p21, that likely 
prevents hyperphosphorylation of Rb in vivo. 8 In 
addition to blockade of cell cycle gene expression, 
interruption of mitogenic signal transduction has 
also been achieved in experimental models. For 
example, Ras proteins are key transducers of mito- 
genie signals from membrane to nucleus in many cell 
types. The local delivery of DNA vectors expressing 
Ras dominant negative mutants, which interfere 
with Ras function, reduced neointimal lesion for- 
mation in a rat carotid artery balloon injury model. 9 
Nitric oxide mediates a number of biologic 
processes that are thought o mitigate neointima 
formation in the vessel wall, such as inhibition of 
VSMC proliferation, reduction of platelet adher- 
ence, vasorelaxation, promotion of endothelial cell 
survival, and possible reduction of oxidative stress. 
In vivo transfer of plasmid DNA coding for 
endothelial cell nitric oxide synthase ( cNOS) has 
been investigated asa potential paracrine strategy to 
block neointimal disease. EcNOS eDNA driven by a 
~-actin promoter and CMV enhancer was transfect- 
ed into the VSMCs of rat carotid arteries after bal- 
loon injury. This model is known to have no signifi- 
cant regrowth of endothelial cells within 2 to 3 
weeks after injury and is therefore capable of loss of 
endogenous ecNOS expression. Results revealed 
expression of the transgene in the vessel wall, along 
with improved vasomotor reactivity and a 70% inhi- 
bition of neointima formation) ° 
An example of a direct cytotoxic approach to the 
prevention of neointima formation is the transfer of 
a "suicide gene," such as the herpes implex virus- 
TK (HSV-TK) gene into VSMCs. With the use of an 
adenoviral vector, HSV-TK was introduced into the 
VSMCs of porcine arteries rendering the smooth 
muscle cells sensitive to the nucleoside analog anci- 
clovir given immediately after balloon injury. After 
one course of ganciclovir treatment, neointimal 
hypcrplasia decreased by about 50%. 11 More recent- 
ly, Pullman and associates 12induced endogenous 
machinery for VSMC "suicide" in a strategy 
designed to inhibit the growth or achieve regression 
of neointimal lesions. This strategy involved anti- 
sense ODN blockade of a "survival" gene known as 
Bcl-x that helps protect cells from activation of pro- 
grammed cell death, or apoptosis. 
Another potentially relevant biologic strategy for 
treatment ofrestenosis is reendothelialization, which 
might be accelerated by local delivery of a proangio- 
genie factor (eg, vascular endothelial cell growth fac- 
tor [VEGF]) at the angioplasty site. This is the basis 
for the only current US clinical trial of gene therapy 
for the prevention of restenosis n the peripheral cir- 
culation, in which the human VEGF gene is admin- 
istered as a "naked" circular DNA plasmid directly 
to the injured arterial wall on the surface of the 
angioplasty balloon, is The investigators hypothesize 
that the low efficiency of this delivery method is bal- 
anced by the high biologic potency of this secreted 
angiogenic cytokine, enabling asignificant local bio- 
logic effect despite poor gene transfer. 
The long-term success of surgical revasculariza- 
tion in the lower extremity and coronary circulations 
has been limited by significant rates (30% in 5 years 
and fi0% in 10 years for both) of autologous vein 
graft failure. No pharmacologic approach as been 
successful at preventing long-term graft diseases of 
neointimal hyperplasia nd subsequent graft athero- 
sclerosis. Gene therapy offers a new avenue for the 
modification of vein graft biology that might lead to 
a reduction in clinical morbidity from graft failures. 
Intraoperative transfection of the vein graft also 
offers an opportunity to combine intact issue DNA 
transfer techniques with the increased safety of ex 
vivo transfection, and a number of studies have doc- 
umented the feasibility of ex vivo gene transfer into 
vein grafts using viral vectors. 
The vast majority of vein graft failures has been 
linked to the neointimal disease that is part of graft 
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remodeling after surgery. Although neointimal hyper- 
plasia contributes to the reduction of  wall stress in 
vein grafts after bypass, this process can also lead to 
luminal narrowing of  the graft conduit during the first 
years after operation. Furthermore,  the abnormal 
neointimal layer, with its production of  proinflamma- 
tory proteins, is believed to form the basis for an 
accelerated form o f  atherosclerosis that causes late 
graft failure. 
Like the arterial bal loon injury model ,  it was 
found that a combinat ion o f  antisense ODN that 
inhibits expression of  at least two cell cycle regulato- 
ry genes could significantly block neointimal hyper- 
plasia in vein grafts. 14 In contrast o arterial balloon 
injury, however, vein grafts are not  only subjected to 
a single injury at the time o f  operation, but are also 
exposed to chronic hemodynamic stimuli for remod- 
eling. Despite these chronic stimuli, a single, intra- 
operative ODN treatment o f  vein grafts resulted in a 
resistance to neointimal hyperplasia that lasted for at 
least 6 months  in the rabbit model.  Abnormal  
endothelial cell function, a significant contr ibutor to 
graft failure, was also shown to be improved by 
ODN inhibition o f  the neointimal disease process.15 
Treatment o f  vein grafts with the E2F decoy ODN 
yielded a similar efficacy as the arterial injury model, 
and along with the antisense treated grafts, was able 
to adapt appropriately to arterial conditions through 
hypertrophy of  the medial layer. Furthermore, these 
genetically engineered conduits proved resistant o 
diet-induced graft atherosclerosis.14,16 
A prel iminary single-center, prospective, ran- 
domized  double-b l ind trial o f  human vein graft 
treatment with E2F decoy ODN has been complet- 
ed. 17 Efficient delivery o f  the ODN is accomplished 
within 15 minutes during the operation by place- 
ment o f  the graft after harvest in a device that expos- 
es the vessel to ODN in physiologic solution and 
allows simultaneous application of  a pressure o f  300 
mm Hg to all sides o f  the vessel, avoiding any poten- 
tial mechanical injury, Delivery to more than 80% of  
graft cells has been documented,  along with effective 
blockade o f  target gene expression. Primary graft 
failure was defined as graft occlusion, or severe 
stenosis requir ing graft revision. Analysis o f  graft 
failure rates 1 year after grafting demonstrated a 
reduction o f  primary failure rates among E2F decoy 
ODN-treated grafts compared with untreated grafts. 
Al though the efficacy o f  this approach requires fur- 
ther validation in large-scale multicenter trials, this 
study demonstrates the safety, feasibility, and suc- 
cessful application o f  gene therapy to the treatment 
o f  a clinically relevant vascular disorder. The success 
o f  this study may have broader implications for other 
forms o f  vascular proliferative disease, restenosis, 
and native arterial atherosclerosis and offers an 
encouraging limpse into the future applicability o f  
genetic-based therapy. 
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RADIATION THERAPY: EXPERIMENTAL AND 
CLINICAL DATA--PREMATURE EXCITEMENT? 
Renu Virmani, MD 
Armed Forces Institute of Pathology 
Washington, DC 
Local intravascnlar radiation therapy has shown 
promise in experimental nimals and in human pre- 
liminary studies for preventing restenosis after 
catheter-based interventions. However, higher sub- 
acute thrombosis rate and "edge effects" in 
brachytherapy and stent-based radiation therapy, 
respectively, have been reported. Therefore, it seems 
reasonable to review the published studies on the 
effect of external beam radiation on coronary disease 
and to compare these data with animal studies. 
Although radiation-induced coronary artery dis- 
ease occurs less fequently than typical coronary 
atherosclerosis, it  occurrence following external beam 
mediasth~al irradiation isno longer in doubt. The pre- 
cise incidence ofradiatiofi-induced accelerated athero- 
sclerosis is difficult to confirm secondary to the high 
prevalence of coronary artery disease in the Western 
population. The linkage of radiation arterial injury and 
subsequent a herosclerosis is strongest in yotmg indi- 
viduals who otherwise lack traditional risk factors for 
coronary atherosclerosis, particularly hyperlipidemia. 
Bovin et al 1 estimated the r lative risk of death from 
radiation-induced coronary artery disease as 1.5 
patients treated with mediastinal radiation with twice 
the number of deaths from coronary disease seen in 
the radiotherapy group with the cohort group. The 
incidence of radiation-induced coronary heart disease 
is greatest when radiation is given for Hodgkin's 
disease as compared with seminoma, breast carcinoma, 
lymphoma, and lung neoplasms. 2-4 
Pathology of radiation-induced heart disease 
Many of the pathologic hanges within the inti- 
rna, media, and adventitia secondary to radiation 
may be difficult to distinguish from typical athero- 
sclerotic oronary disease. Our experience is similar 
to that published by Brosius et al,5 in that the media 
is more severely destroyed and the adventitia is 
markedly thickened and fibrotic in radiation- 
induced coronary disease as compared with nonradi- 
ation-induced coronary therosclcrosis. 
Overall, the intimal plaque in radiation-induced 
arterial pathology is similar to common atherosclero- 
sis, although there is a trend toward greater lipid and 
calcium content and a decrease in fibrous tissue in 
radiated than in nonradiated atherosclerotic plaques. 5 
The disease varies from single vessel involvement toall 
four vessels involved by more than 75% cross-section- 
al area luminal narrowing. In the study by Brosius et 
al,5 at least 25% of the major coronary arteries were 
narrowed 75% to 100% in cross-sectional rea, an 
average of one of four major coronary arteries per 
patient. The proximal half of the right and left anteri- 
or descending coronary arteries in the radiated group 
was more often significantly narrowed than in the dis- 
tal portion of these arteries. 5 Intramyocardial coro- 
nary thickening was only seen in the radiated group 
and was most often seen in the right ventricle. ~
Endocardial thickening was also prominent and was 
observed in 75% of radiated patients with the highest 
frequency in the right ventricle. Similarly, valvular 
thickening was also common and occurred in over 
80% of patients with the tricuspid valve most fre- 
quently involved. ~Nearly all patients develop ericar- 
dial and epicardial fibrosis folloMng radiation with or 
without adhesions, and obliteration of the pericardial 
space is not unusual. The study by Brosius et al was 
published in 1981, and since that time, a greater 
understanding of the radiation injury to tissues has 
emerged with more attention paid to heart shielding. 
However, radiation-induced heart disease is still 
encountered; in our laboratory, we have seen recent 
cases in patients receiving radiation therapy for breast 
and lung malignancies. 
Pathology of  radiat ion- induced pigs coronary 
disease and rabbit iliac arteries after placement of  
[3-particle mitting stents 
We have recently reported our findings following 
placement of b-particle-emitting radioactive stents 
(0.15-23.0 ~tCi of 32P) in pig coronary arteries at 1 
and 6 months. We observed medial thinning and 
necrosis at 1 month in stents with more than 3 ~tCi 
radioactivity. The neointima mostly consisted of 
fibrin, red cells, and a few inflammatory cells. 
However, the lumen was significantly larger in radi- 
ated stented arteries than nonradiated control stents. 
At 1 ~tCi, the media was focally thinned, and the 
neointima consisted of smooth muscle cells in a 
matrix rich in proteoglycans with red cell accumula- 
tion around stent struts. In addition, there were 
greater numbers of neocapillarics around stent struts 
than in control nouradiated stented arteries, and the 
lumen was significantly smaller in the radiated group 
